Reducing overall medical costs while improving treatment requires an accurate and optimized medication regimen, yet Adverse Drug Reactions (ADRs) are the 4th leading cause of death, costing the United States more than $138 billion annually.
hc1 PGx Advisor is the only unified platform that combines conventional Medication Therapy Management (MTM), PharmacoGenomics (PGx), clinical lab data and integrated engagement and monitoring workflows specific to the individual patient.
Healthcare providers are under significant pressure to provide high quality, high-value care. While 82% of the U.S. population is prescribed at least one medication, the FDA estimates approximately 50% of those drugs are ineffective or harmful for the specific patient.
An individual’s unique genetic profile influences their ability to metabolize many common prescription drugs. Ensuring patients are prescribed the most effective medications with the least amount of risk is critical to driving improved patient outcomes and reducing overall medical costs.
How can providers access the additional clinical information they need to personalize prescribing without added time or cost?
PGx Advisor combines conventional Medication Therapy Management (MTM), PharmacoGenomics, and integrated engagement and monitoring workflows specific to the individual patient. The drugs with genetic implications are not rare: 52% of the 50 most common drugs have genetic implications for efficacy and patient safety.
This unique approach ensures the right patient gets the right prescription based on their unique genetic traits.
PGx Advisor produces a detailed Rx Scoring Report using a real-time database of drug interactions, FDA warnings and pharmacogenomic markers combined with prescription and medical claims, formulary and demographic data.
hc1 PGx Advisor was chosen as Tech Product of the Year during TechPoint’s 21st annual Mira Awards, an awards gala to honor “Best of Tech” in Indiana. Accepted by Reed Richardson, Vice President of Rx Business Operations, this award commemorates the success of the hc1 PGx Advisor in improving patient care.
hc1 PGx Advisor was chosen as Tech Product of the Year during TechPoint’s 21st annual Mira Awards, an awards gala to honor “Best of Tech” in Indiana. Accepted by Reed Richardson, Vice President of Rx Business Operations, this award commemorates the success of the hc1 PGx Advisor in improving patient care.
Improve patients’ health status through personalized prescribing informed by the latest genomic science. Reduce costs by eliminating ineffective and harmful drugs from therapy regimens.
As a clinician utilizes PGx Advisor, they are able to combine the patient’s PGx results with other key pieces of information, such as lifestyle, family history, medical history, allergies, and past medications, to determine the right drug and right dose for the patient.
Approximately 50% of patients do not take their medications as prescribed. Individualized dosing, increased efficacy, maximized safety, and overall higher patient satisfaction result in less non-adherence.
The right medication at the right dose the first time drives down costs to the patient and the health system, improving short-and long-term outcomes.
Gain continuous insight into healthcare savings through continuous monitoring of prescription and medical claims to provide leaders with the real-time measurement.
